C.R. Bard Inc. (BCR) Quarterly Valuation – March 2014

Bard_logoBenjamin Graham taught that Intelligent Investors must do a thorough fundamental analysis of investment opportunities to determine their intrinsic value and inherent risk.  This is best done by utilizing a systematic approach to analysis that will provide investors with a sense of how a specific company compares to another company.  By using the ModernGraham method one can review a company’s historical accomplishments and determine an intrinsic value that can be compared across industries.  What follows is a specific look at how C.R. Bard Inc. fares in the ModernGraham valuation model.

Company Profile (obtained from Google Finance): C. R. Bard, Inc. (Bard) is engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. As of December 31, 2011, the Company sold a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. The Company participates in the markets for vascular, urology, oncology and surgical specialty products. Bard also has a product group of other products. Through subsidiaries and a joint venture, Bard markets its products to customers in over 100 countries outside the United States. The Company’s principal international markets were in Europe and Japan as of December 31, 2011. On November 10, 2011, Bard acquired Medivance, Inc. On December 16, 2011, the Company acquired Lutonix, Inc.

BCR Chart

BCR data by YCharts

Defensive Investor – must pass at least 6 of the following 7 tests: Score = 5/7

  1. Adequate Size of Enterprise – market capitalization of at least $2 billion – PASS
  2. Sufficiently Strong Financial Condition – current ratio greater than 2 – PASS
  3. Earnings Stability – positive earnings per share for at least 10 straight years – PASS
  4. Dividend Record – has paid a dividend for at least 10 straight years – PASS
  5. Earnings Growth – earnings per share has increased by at least 1/3 over the last 10 years using 3 year averages at beginning and end of period – PASS
  6. Moderate PEmg ratio – PEmg is less than 20 – FAIL
  7. Moderate Price to Assets – PB ratio is less than 2.5 or PB x PEmg is less than 50 – FAIL

Enterprising Investor – must pass at least 4 of the following 5 tests or be suitable for a defensive investor: Score = 5/5

  1. Sufficiently Strong Financial Condition, Part 1 – current ratio greater than 1.5 – PASS
  2. Sufficiently Strong Financial Condition, Part 2 – Debt to Net Current Assets ratio less than 1.1 – PASS
  3. Earnings Stability – positive earnings per share for at least 5 years – PASS
  4. Dividend Record – currently pays a dividend – PASS
  5. Earnings growth – EPSmg greater than 5 years ago – PASS

Valuation Summary

Key Data:

Recent Price $146.69
MG Value $166.39
MG Opinion Fairly Valued
Value Based on 3% Growth $91.41
Value Based on 0% Growth $53.58
Market Implied Growth Rate 7.38%
Net Current Asset Value (NCAV) -$11.14
PEmg 23.27
Current Ratio 3.56
PB Ratio 5.44

Balance Sheet – 12/31/2013

Current Assets $2,090,400,000
Current Liabilities $586,500,000
Total Debt $1,405,700,000
Total Assets $5,041,100,000
Intangible Assets $2,264,400,000
Total Liabilities $2,952,900,000
Outstanding Shares 77,440,000

Earnings Per Share

2013 $8.55
2012 $6.28
2011 $3.76
2010 $5.38
2009 $4.65
2008 $4.06
2007 $3.84
2006 $2.55
2005 $3.12
2004 $2.82

Earnings Per Share – ModernGraham

2013 $6.30
2012 $5.06
2011 $4.42
2010 $4.53
2009 $3.95
2008 $3.49

Dividend History

BCR Dividend Chart

BCR Dividend data by YCharts


C.R. Bard Inc. is a very intriguing company for Enterprising Investors, having passed all five of the investor type’s requirements.  The company does not quite qualify for the Defensive Investor due to the high PEmg and PB ratios.  As a result, Enterprising Investors should feel very comfortable proceeding with further research into the company but should also compare it to other opportunities through a review of ModernGraham’s valuation of Medtronic (MDT) and ModernGraham’s valuation of Covidien (COV).  From a valuation perspective, the company appears to be fairly valued, having exhibited solid growth in EPSmg (normalized earnings) from $3.95 in 2009 to $6.30 in 2013.  This demonstrated level of growth supports the market’s implied estimate of 7.38% earnings growth and leads the ModernGraham valuation model to estimate an intrinsic value within a margin of safety relative to the price.

The next part of the analysis is up to individual investors, and requires discussion of the company’s prospects.  What do you think?  What value would you put on C.R. Bard Inc. (BCR)?  Where do you see the company going in the future?  Is there a company you like better?  Leave a comment on our Facebook page or mention @ModernGraham on Twitter to discuss.

If you like our valuations, why not check out ModernGraham Stocks & Screens?  It’s a great way to review the valuations while screening for things like low PE ratio, undervalued companies, etc.!

Disclaimer:  The author did not hold a position in C.R. Bard Inc. (BCR) or any of the other companies mentioned in the article at the time of publication and had no intention of changing that position within the next 72 hours.

Logo taken from wikipedia; this article is not affiliated with the company in any manner.





Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.